Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
about
The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemiaPotential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemiaAnti-CD19 Monoclonal Antibodies: a New Approach to Lymphoma TherapyNovel immunotherapies in lymphoid malignanciesBlinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaFrom monoclonal antibodies to chimeric antigen receptors for the treatment of human malignanciesBlinatumomab: enlisting serial killer T-cells in the war against hematologic malignanciesTrial Watch: Tumor-targeting monoclonal antibodies in cancer therapyMonoclonal antibodies in acute lymphoblastic leukemiaBispecific T-cell engagers for cancer immunotherapy.In vivo imaging of therapy-induced anti-cancer immune responses in humans.High-content molecular profiling of T-cell therapy in oncologyImmunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor siteCatch me if you can: Leukemia Escape after CD19-Directed T Cell ImmunotherapiesClinical use of blinatumomab for B-cell acute lymphoblastic leukemia in adultsAntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cellsJanus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisCD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Clinical Pharmacology and Translational Aspects of Bispecific AntibodiesIdentification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.Managing cytokine release syndrome associated with novel T cell-engaging therapies.Engineered T cells for cancer therapy.Antibody-based immunotherapy for malignant glioma.T cell-recruiting triplebody 19-3-19 mediates serial lysis of malignant B-lymphoid cells by a single T cellToxicity management for patients receiving novel T-cell engaging therapies.Frontier of therapeutic antibody discovery: The challenges and how to face them.Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies.Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinicNovel agents for the treatment of childhood acute leukemia.Engager T cells: a new class of antigen-specific T cells that redirect bystander T cellsB7H6-Specific Bispecific T Cell Engagers Lead to Tumor Elimination and Host Antitumor ImmunityProfile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia.Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110Blinatumomab and Pembrolizumab.Physiologically Based Pharmacokinetic Model to Assess the Influence of Blinatumomab-Mediated Cytokine Elevations on Cytochrome P450 Enzyme ActivityRedirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.CEA/CD3 bispecific antibody MEDI-565/AMG 211 activation of T cells and subsequent killing of human tumors is independent of mutations commonly found in colorectal adenocarcinomasSystemic administration of a bispecific antibody targeting EGFRvIII successfully treats intracerebral glioma.Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
P2860
Q26744280-BE6D2BE8-E306-4AAA-9292-1030499F297AQ26764903-FC2E397E-F62A-47E3-820E-0525EF70F64FQ26775363-ABFCF9E8-ED84-45B7-96A9-0D8F87C25D73Q26777394-826963D6-DA78-4E56-B6C9-E1EFD5D29DA2Q26785828-95824234-68EC-43AF-B7A6-62CE9395F858Q26852919-54E8C001-826C-40FE-A5EE-67CDF46E2A5BQ26865838-0B56733D-54F0-4E1A-84A6-2F687003B378Q26993238-AF93285F-C8F7-42E7-BB6F-E35D339952F2Q27022540-D6436F32-A087-40FB-9E18-1A3C28626BDAQ27693313-C359A0D4-72AF-4D29-BAFB-3D6823E956F0Q27693338-253F3C9B-EEE3-4216-824E-B15900269ACBQ28066792-7F20F8DA-14D7-491C-AB64-9F0A23C67D36Q28066935-3385BA70-34F9-4C9E-AB51-A10EF0083914Q28072131-7666D2BF-9585-4C4F-BFC0-7A6F5F43EB75Q28075764-F0335D10-C750-4898-A7EE-7C38483E5493Q30637447-D48BFA3B-4523-4DEA-B7B2-44B692BAB52EQ33429617-EDAA7DD4-EBF3-448D-9865-DE3AE6704DF3Q33585293-5A87569F-B286-48F0-96DF-8718205486EFQ33648086-B9AB5C17-E39E-4778-9948-F3486D9ADF4CQ33738328-FB7353A1-875A-4978-A2FD-CAEBC9264723Q33993517-A1C9DEC8-1F74-4B9D-AE9F-0DF2CFAB5661Q34080368-52E05CC4-7259-4EA5-821F-BC040609472DQ34120472-E1AF1312-BCBF-4B54-91EB-F25C5BB9D7BEQ34227769-E0130B47-6D7F-4977-843C-DE464AD8870BQ34343346-7B4F291B-AC19-4CDC-8B88-02A5D8D3B605Q34527769-BBE2CABB-0B27-40D0-94D8-FF34C6FA5514Q34548319-B4837549-243E-4403-A190-1CF4C29F364FQ34748489-220C6AB6-C0A5-4AD3-BB5B-DC7D79F1328BQ34817365-7EF249A6-A70F-49BA-901A-893DC53B798AQ35192790-E47D493A-1892-4EF4-B107-2DA58B17D61DQ35591391-BE85C65B-87E0-4259-A21A-EF30C9564C91Q35613233-1615523F-B2A0-4F68-A58B-695A372E5535Q35799427-16B374A3-53E0-437C-A2FC-353B82CEDD1FQ35824663-2ABBF30D-2B21-4D46-8D61-BBD09C6D7A28Q36110034-BEFEDCCC-59F1-4BCF-AD8F-E3DAF08C138DQ36118294-A14318A1-7654-442C-ACAC-04B4D00E260FQ36131489-C2B35249-76C6-4F4A-A9A1-B850EAC51328Q36211422-7E02D106-1D52-453F-8EDE-F2EFE4A85301Q36512160-EC621988-3DDE-4B2D-98F0-8F7E72DFAB79Q36700470-11D0573B-5821-4421-A087-B4258A0BBBA0
P2860
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Immunopharmacologic response o ...... ic BiTE antibody blinatumomab.
@en
type
label
Immunopharmacologic response o ...... ic BiTE antibody blinatumomab.
@en
prefLabel
Immunopharmacologic response o ...... ic BiTE antibody blinatumomab.
@en
P2093
P1433
P1476
Immunopharmacologic response o ...... ic BiTE antibody blinatumomab.
@en
P2093
Andreas Viardot
Andreas Wolf
Christian Brandl
Dieter Hoelzer
Dirk Nagorsen
Evelyn Degenhard
Gerhard Zugmaier
Mariele Goebeler
Matthias Klinger
Matthias Stelljes
P304
P356
10.1182/BLOOD-2012-01-400515
P407
P577
2012-05-16T00:00:00Z